SURVYR

CLMT

Calumet, Inc.
$49.89
+$0.00 (0.00%)Oct 28 close
Basic Materials CompareTechnicals
-11%+41%+93%+145%+198%Oct 2025Oct 2026Apr 202652w high $59.8752w low $17.85
CLMTSPY
Wall St. Highest PT $75.00 (+50.3%) Wall St. Avg PT $55.80 (+11.8%)
$18$33$48$62$77POC $20Hi $75Avg $56
Underwater Drawdown %Max DD -16.5%Current -15.5%
0.0%-16.5%
Relative Strength vs SPY+134.2% vs SPYOutperforming
+209%0%-209%
1W
−$2.83 (5.38%)
1M
−$2.72 (5.17%)
3M
+$7.49 (17.67%)
6M
+$17.36 (53.37%)
YTD
+$30.02 (151.08%)
1Y
+$29.99 (150.70%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
6 analysts · mean score 2.33
1 = Strong Buy · 5 = Sell
Strong Buy00%
Buy233%
Hold467%
Underperform00%
Sell00%
Wall Street consensus
Analyst price targets
Current price$49.89
Average target$55.80
+$5.91 (+11.8%) upsideaverage target vs current price
CurrentAverageMedian
Low$40.00
Median$57.00
High$75.00
12-month Wall Street target range
Recent analyst rating changes · 30
Reiterated
2026-09-02 · HC Wainwright & Co. reiterated Buy on CLMT
Reiterated
2026-08-25 · UBS reiterated Neutral on CLMT
Reiterated
2026-08-18 · Goldman Sachs reiterated Neutral on CLMT
Reiterated
2026-08-12 · TD Cowen reiterated Hold on CLMT
Reiterated
2026-07-30 · Goldman Sachs reiterated Neutral on CLMT
Reiterated
2026-03-30 · HC Wainwright & Co. reiterated Buy on CLMT

Third-party ratings, not SURVYR.'s views.

Health check

Financial health
DistressGrey zoneSafe
Distress zone
Altman Z-score 1.3
Above 2.99 is the safe zone, below 1.81 the distress zone.
Quality
WeakAverageStrong
Average
Piotroski F-score 6 of 9
See the tests
  • ✗Positive net income
  • ✓Positive operating cash flow
  • ✓Return on assets improved
  • ✓Cash flow above net income
  • ✗Long-term debt / assets fell
  • ✓Current ratio improved
  • ✗No share dilution
  • ✓Gross margin improved
  • ✓Asset turnover improved

Computed by SURVYR. from the company's SEC filings (latest balance sheet Jun 30, 2026). Descriptive, not a forecast.

Key stats & company

Market value$4.4B
P/E (next 12 months, estimated)15.6
52-week range$17.85 – $59.87
Revenue growth (latest quarter vs a year ago)+40.8%
Dividend yieldNo dividend
Analyst consensusBuy (5)
Average analyst price target$55.80 (+12%)

What they do

Calumet, Inc. manufactures, formulates, and markets a slate of specialty branded products and renewable fuels in North America and internationally. It operates through Specialty Products and Solutions; Performance Brands; and Montana/Renewables segments. The Specialty Products and Solutions segment manufactures and markets various solvents, waxes, customized lubricating oils, white oils, petrolatums, gels, esters, and other products.

Basic Materials · Specialty Chemicals
Valuation and fundamentals

Valuation & fundamentals

Bottom line
Looks expensive
Model read-out from the numbers below, not advice. Score -4 (DCF counts double).
▼DCF (base case)below the price by 74%
•Piotroski F-score6/9
▼Altman Z1.3 (distress)
▼Net debt / EBITDA11.1x
•Analyst target+12% (5 analysts)

Discounted cash flow

Bear
$-4
-109%
growth 11% · disc. 9.2% · term. 2.0%
Base
$13
-74%
growth 18% · disc. 8.2% · term. 2.5%
Bull
$41
-18%
growth 23% · disc. 7.2% · term. 3.0%

A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.

Reverse DCFfor context, not a signal
Today's price assumes free cash flow grows about 23% a year for 10 years.
Implied
+23%/yr
FCF, last 3 yrs
n/a
FCF, last 5 yrs
n/a
Revenue, last 3 yrs
-4%/yr
Revenue, last 5 yrs
n/a
Same inputs as the DCF above: trailing free cash flow 0.1B, 8.2% discount rate, 2.5% growth after year 10, net debt and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2025; "n/a" means too little history or a negative starting year.
Edit assumptions · recalculates instantly
Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.78 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs sector

Forward EPS $3.20 vs trailing $-1.55. Forward P/E uses analysts' next-12-month estimate.

Quality & financial health

Gross margin
6.6%
Operating margin
1.0%
FCF margin
1.6%
Net margin
-3.0%
Return on equity
–
Return on invested capital
3.8%
Net debt / EBITDA
11.1×
Current ratio
0.8×
Interest cover
0.2×
Cash conversion (OCF/NI)
–
Piotroski F-score 6/9 · last two fiscal years
✗ Positive net income✓ Positive operating cash flow✓ Return on assets improved✓ Cash flow above net income✗ Long-term debt / assets fell✓ Current ratio improved✗ No share dilution✓ Gross margin improved✓ Asset turnover improved

Altman Z-score 1.3 (distress zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.

Analysts

Mean target
$56
+12%
Analysts
5
Buy
Range
$40–$75
low – high
● price · ◆ mean target

Annual history

FYRevenueNet incomeFree cash flow
2025$4.1B$-33.8M$56.6M
2024$4.2B$-222.0M$-123.1M
2023$4.2B$48.1M$-286.7M
2022$4.7B$-173.3M$-435.6M

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR -4.1%.

For information only · Important disclosures

Grades vs sector

No sector grades for CLMT yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
Momentum Top 15
Outside this model's universe or screens
Momentum Blend
Not in the current book
New Highs Growth
Outside this model's universe or screens
SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
SURVYR. Long Book
Not in the current book

Earnings & events

CLMT earningsNext report in 9 days
Next report · quarter Sep 2026
Fri Nov 6, 2026Before the open
EPS consensus$1.80 range $1.80–$1.80
Revenue consensus$1.3B 6 analysts
Last 4 quarters · EPS vs estimate
Aug 7, 2026$0.68est $0.16+323.7%Above estimates
May 8, 2026-$0.41est -$0.63+35.0%Above estimates
Feb 27, 2026-$0.18est -$0.45+59.9%Above estimates
Nov 7, 2025$0.20est -$0.43+147.6%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-28 07:02:36 ET
24-1125-0225-0525-0825-1126-0226-0526-08-0.860.68
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$1.4B+40.8%
2026-03-31$1.0B–
2025-12-31$1.0B–
2025-09-30$1.1B–
2025-06-30$1.0B–

Recent dividends

2016-01-29: $0.685 · 2015-10-30: $0.685 · 2015-07-31: $0.685 · 2015-05-01: $0.685 · 2015-01-30: $0.685 · 2014-10-31: $0.685 · 2014-07-31: $0.685 · 2014-05-01: $0.685

News & catalysts

More news
Diesel Tightness Is Putting CVR Energy Stock And Refiners Back In Focus
Simply Wall St. · 21h ago
1 profitable stock with impressive fundamentals and 2 facing headwinds
StockStory · Oct 23
Are Oils-Energy Stocks Lagging Calumet, Inc. (CLMT) This Year?
Zacks · Oct 23
3 U.S. Refining Stocks Retail Investors Are Watching After The Russia Sanctions Waiver
Simply Wall St. · Oct 16
Calumet Issues Redemption Notice for $150 Million of 9.75% Senior Notes due 2028
PR Newswire · Oct 15
Rating changes
Reiterated
2026-09-02 · HC Wainwright & Co. reiterated Buy on CLMT
Reiterated
2026-08-25 · UBS reiterated Neutral on CLMT
Reiterated
2026-08-18 · Goldman Sachs reiterated Neutral on CLMT
Reiterated
2026-08-12 · TD Cowen reiterated Hold on CLMT
Reiterated
2026-07-30 · Goldman Sachs reiterated Neutral on CLMT
Reiterated
2026-03-30 · HC Wainwright & Co. reiterated Buy on CLMT

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Mawer Stephen P
Director · 2026-09-25
Sell
$0
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed 2026-10-28 07:02:36 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

Coteau 0.9 · Oct 21, 2026